These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
568 related articles for article (PubMed ID: 19421058)
61. [Epidemiology and therapy of infections caused by Neisseria meningitidis]. Skoczyńska A; Hryniewicz W Pol Merkur Lekarski; 2003 Nov; 15(89):459-62. PubMed ID: 14969144 [TBL] [Abstract][Full Text] [Related]
62. [Clinical aspects and outcome of meningococcal disease due to Neisseria meningitidis of serogroup W135 in 5 children]. Faye A; Mariani-Kurkjian P; Taha MK; Louzeau C; Bingen E; Bourrillon A Arch Pediatr; 2005 Mar; 12(3):291-4. PubMed ID: 15734127 [TBL] [Abstract][Full Text] [Related]
63. [Anti-meningococcal vaccines]. Taha MK; Alonso JM Rev Prat; 2008 Dec; 58(19):2099-101. PubMed ID: 19213536 [TBL] [Abstract][Full Text] [Related]
64. Protecting the world against meningitis: new recommendations from the CDC's advisory committee on immunization practices. Cyrus SS; J Am Osteopath Assoc; 2011 Oct; 111(10 Suppl 6):S17-9. PubMed ID: 22086889 [TBL] [Abstract][Full Text] [Related]
65. A hypothetical explanatory model for meningococcal meningitis in the African meningitis belt. Mueller JE; Gessner BD Int J Infect Dis; 2010 Jul; 14(7):e553-9. PubMed ID: 20018546 [TBL] [Abstract][Full Text] [Related]
66. Update: Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, October 2005-February 2006. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2006 Apr; 55(13):364-6. PubMed ID: 16601664 [TBL] [Abstract][Full Text] [Related]
67. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci. Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907 [TBL] [Abstract][Full Text] [Related]
69. MCV vaccination in the presence of vaccine-associated Guillain-Barré Syndrome risk: a decision analysis approach. Cho BH; Clark TA; Messonnier NE; Ortega-Sanchez IR; Weintraub E; Messonnier ML Vaccine; 2010 Jan; 28(3):817-22. PubMed ID: 19879992 [TBL] [Abstract][Full Text] [Related]
70. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Galloway Y; Stehr-Green P; McNicholas A; O'Hallahan J Int J Epidemiol; 2009 Apr; 38(2):413-8. PubMed ID: 18988650 [TBL] [Abstract][Full Text] [Related]
71. [Characteristics of meningococcal meningitis in children in France]. Levy C; Taha MK; Weill Olivier C; Quinet B; Lécuyer A; Alonso JM; Cohen R; Bingen E; Arch Pediatr; 2008 Dec; 15 Suppl 3():S105-10. PubMed ID: 19268239 [TBL] [Abstract][Full Text] [Related]
74. Epidemiology and risk factors for serogroup X meningococcal meningitis during an outbreak in western Kenya, 2005-2006. Mutonga DM; Pimentel G; Muindi J; Nzioka C; Mutiso J; Klena JD; Morcos M; Ogaro T; Materu S; Tetteh C; Messonnier NE; Breiman RF; Feikin DR Am J Trop Med Hyg; 2009 Apr; 80(4):619-24. PubMed ID: 19346388 [TBL] [Abstract][Full Text] [Related]
75. In brief: a booster dose of meningococcal vaccine for adolescents. Med Lett Drugs Ther; 2011 May; 53(1364):37. PubMed ID: 21566543 [No Abstract] [Full Text] [Related]
76. In brief: prevention of meningococcus B disease. Med Lett Drugs Ther; 2013 Dec; 55(1431):97. PubMed ID: 24322662 [No Abstract] [Full Text] [Related]